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In a letter to the editor, Damment 1 from Shire Pharmaceuticals has questioned the interpretation of the results from our recently published study in this journal. 2 We looked at the tissue accumulation of lanthanum in kidney, bone, and liver from normal and uremic lanthanumtreated rats. In Damment's letter, he suggests that the only appropriate comparison is the one between the lanthanum-treated normal and lanthanum-treated uremic rats. When looking at tissue accumulation, the appropriate control for lanthanum-treated uremic rats is untreated uremic rats. When we made this comparison, we demonstrated a progressive accumulation of lanthanum in liver over the entire course of the study. We also observed that uremia enhances the accumulation of lanthanum as has been shown by other investigators. 3, 4 In his letter, Damment includes a graph showing that lanthanum accumulation reaches steady-state conditions in longer term studies. This study, however, was not performed in uremic rats, but in normal animals. As with Damment's study, we also saw that lanthanum accumulation in liver begin to plateau in lanthanum-treated normal rats. 2 Lanthanum, however, will not be prescribed to normal individuals; thus, these results have no relevance for hemodialysis patients. On the other hand, Bervoets et al. 3 showed significantly greater gastrointestinal absorption of lanthanum in renal failure. This explains why we see a greater and progressive accumulation of lanthanum in the uremic state. Initial concern for lanthanum use had centered around its potential effects on bone and brain, as these were the tissues adversely affected by aluminumcontaining phosphate binders. 5 We state in our paper that lanthanum likely has no effect on either of these tissues or for that matter, kidney. Given the experience with aluminum-containing phosphate binders, we must be certain that treatments designed to benefit our patients will not, in fact, harm them. The jury is still out. 
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